AZ13767370 (Compound 13)

Mechanism of action: Covalent Erk1/2 inhibitor


Preclinical pharmacology

Compound 13 inhibits Erk2 with a potency of 0.0069 (Km ATP, 120µM) and 0.0085µM (1mM  ATP concentration) in a biochemical RapidFire Mass Spectrometry assay.

In cellular assays using an A375 cell line (b-RAFV600E mutation), compound 13 inhibits pERK and pRSK with an IC50 of 0.022 and 0.065µM respectively.

The covalent mechanism action of this series was confirmed through x-ray crystal structures, mass spec studies and time-course cellular assays.


Suitable for and exclusions

Restricted to preclinical oncology studies (proposals) only. The compound would make an ideal in vitro tool compound, with the potential of being an in vivo mouse probe if co-dosed with ABT (see publication for details of mouse PK).

Additional Information


Publications for this compound

Find out more about this compound by reading related Publications:

Journal of Medicinal Chemistry

Structure-Guided Design of Highly Selective and Potent Covalent Inhibitors of ERK1/2


Gene information from the NCBi

This compound works on the following genes: